Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11,377,077 | $12,573,112 | $17,308,298 | $16,529,541 |
| - Cash | $929,026 | $477,010 | $1,710,751 | $1,541,048 |
| + Debt | $7,612,426 | $6,135,285 | $7,116,322 | $7,096,070 |
| Enterprise Value | $18,060,477 | $18,231,387 | $22,713,869 | $22,084,563 |
| Revenue | $2,263,576 | $2,354,554 | $2,237,215 | $2,289,463 |
| % Growth | -3.9% | 5.2% | -2.3% | – |
| Gross Profit | $2,263,576 | $2,354,554 | $2,237,215 | $2,289,463 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $1,556,325 | $1,887,275 | $423,695 | $1,430,339 |
| % Margin | 68.8% | 80.2% | 18.9% | 62.5% |
| Net Income | $858,983 | $1,134,834 | $42,832 | $619,728 |
| % Margin | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS Diluted | 1.91 | 2.53 | 0.1 | 1.49 |
| % Growth | -24.5% | 2,430% | -93.3% | – |
| Operating Cash Flow | $2,768,986 | $2,987,802 | $2,143,980 | $2,017,536 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $2,768,986 | $2,987,802 | $2,143,980 | $2,017,536 |